High Unmet need for Molnupiravir’–US Infectious Diseases expert says

THERE is a pressing need for a convenient drug like Molnupiravir to use in the treatment of COVID-19 patients, a US infectious diseases expert told a webinar.
This oral antiviral monotherapy will be considered for treatment of COVID-19 in adults.
Molnupiravir is considered to have broad-spectrum activity against a range of RNA viruses including SARS-CoV-2, which causes COVID-19. Molnupiravir works by inhibiting replication of SARS-CoV-2.
Most people who become ill with COVID-19 will be able to recover at home. Dr Robert Grossbert most COVID-19 patients have mild or moderate illness.
“Most COVID-19 patients fit the mild to moderate illness category so there is an unmet need in how to treat those patients,” he said. “In patients who have mild to moderate disease right now the options are very limited. So symptom management, treating their cough or body aches etc.”
Added Dr Grossbert: “In terms of antiviral treatment only drugs used in US outside of a clinical trial are monoclonal antibodies. That is limitedly available to actually get an intravenous get. There is still limited access even in the US.”
Dr Grossbert also noted that there is this appeal of an oral convenient drug that has efficacy over a short course.
“So there is definitely an unmet need,” he said.
To date there is no definitely effective therapy for COVID-19 patients.
“Therefore, the key management for of COVID-19 patients include a variety of supportive measuures including early diagnosis. So most of the treatments we use work when early,” Dr Grossbert said.
The Centre for Diseases Control (CDC) states that early effective treatment of any disease can help avert progression to more serious illness, especially for patients at high risk of disease progression and severe illness, with the additional benefit of reducing the burden on healthcare systems.
“A number of novel therapeutics (e.g., monoclonal antibodies) are available under EUA for early outpatient treatment,” says CDC.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 Comments
scroll to top